Variability of raltegravir plasma levels in the clinical setting

Pharmacology

Volumn 92, Issue 1-2, 2013, Pages 43-48

  Fortuna, Serena ^a   Fabbiani, Massimiliano ^a   Digiambenedetto, Simona ^a   Ragazzoni, Enzo ^a   Lisi, Lucia ^a   Cauda, Roberto ^a   Navarra, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Inter subject variability; Intra subject variability; Raltegravir; Therapeutic drug monitoring

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MINIMUM PLASMA CONCENTRATION; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; LAMIVUDINE; ORGANOPHOSPHONATES; PYRROLIDINONES;

EID: 84880421835     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000351851     Document Type: Article

References (27)

1. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD, Protocol 005 Team: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-1269.
2. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA: Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-1663.
3. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA: Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83: 293-299.
4. Iwamoto M, Wenning LA, Mistry GC, Petry AS, Liou SY, Ghosh K, Breidinger S, Azrolan N, Gutierrez MJ, Bridson WE, Stone JA, Gottesdiener KM, Wagner JA: Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008; 47: 137-140.
5. Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M: Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-4232.
6. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M: Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52: 3253-3258.
7. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA: Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008; 52: 4338-4343.
8. Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, Hanley WD, Jin B, Harvey CM, Breidinger SA, Azrolan N, Farmer HF Jr, Isaacs RD, Chodakewitz JA, Stone JA, Wagner JA: Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489-492.
9. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M: Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852-2856.
10. Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, Calmy A: Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 4619-4625.
11. Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E: Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit 2010; 32: 782-786.
12. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Cuenca L, Simiele M, Baietto L, Calcagno A, Moss D, Bonora S, Sorian V, Back DJ, Owen A, Di Perriet G: Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit 2012; 34: 232-235.
13. Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, Bracciale L, Cauda R, Navarra P, De Luca A: Darunavir/ ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res 2011; 63: 249-253.
14. Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, Landonio S, Boreggio G, Rizzardini G, Clementiet E: Co-administration of raltegravir reduces daily darunavir exposure in HIV-1-infected patients. Pharmacol Res 2012; 65: 198-203.
15. Fabbiani M, Navarra P, Cauda R, De Luca A, Di Giambenedetto S: Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? J Acquir Immune Defic Syndr 2012; 60:e18-e20.
16. Do VT, Higginson RT, Fulco PP: Raltegravir dosage adjustment in HIV-infected patients receiving etravirine. Am J Health Syst Pharm 2011; 68: 2049-2054.
17. Mnard A, Solas C, Mokthari S, Bregigeon S, Drogoul MP, Tamalet C, Lacarelle B, Martin IP: Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009; 23: 869-871.
18. Patel N, Abdelsayed S, Veve M, Miller CD: Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011; 45: 317-324.
19. Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B: Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010; 69: 51-57.
20. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr, ACTG A5262 Team: HYPERLINK "http://www. ncbi.nlm.nih.gov/pubmed/21857490" Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25:2113-2122.
21. Fortuna S, Ragazzoni E, Lisi L, Di Giambenedetto S, Fabbiani M, Navarra P: Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples. Ther Drug Monit 2013; 35: 258-263.
22. Anker M, Corales RB: Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 2008; 17: 97-103 .
23. Yilmaz A, Gissln M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW: Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.
24. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf. Access verified on Apr 29, 2013.
25. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C: Swiss HIV Cohort Study Group Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother 2012; 56: 2959-2966.
26. Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, Baldelli S, Pellegrini M, Galli M, Clementi E: Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 2012; 67: 460-464.
27. Fayet Mello A, Buclin T, Franc C, Colombo S, Cruchon S, Guignard N, Biollaz J, Telenti A, Decosterd LA, Cavassini M: Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J Antimicrob Chemother 2011; 66: 1573-1581.